An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients-Reference-Cited by-同舟云学术

An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients

Published:2021-06 Issue: Volume:Volume 14 Page:2461-2498
ISSN:1178-6973
Container-title:Infection and Drug Resistance
language:en
Short-container-title:IDR

Author:

Gatti Milo,Viaggi Bruno,Rossolini Gian Maria^ORCID,Pea Federico^ORCID,Viale Pierluigi

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases,Pharmacology

Reference114 articles.

1. Severe Sepsis and Septic Shock

3. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017

4. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study

5. Antimicrobial Resistance in the Intensive Care Unit

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On the assessment of the role of new antibiotics in pharmacotherapy algorithms for complicated intra-abdominal infections (literature review);Journal of Volgograd State Medical University;2024-08-05

2. Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use;World Journal of Emergency Surgery;2024-06-08

3. Intra-abdominal infections survival guide: a position statement by the Global Alliance For Infections In Surgery;World Journal of Emergency Surgery;2024-06-08

4. International guidelines for the treatment of carbapenem-resistant Gram-negative Bacilli infections: A comparison and evaluation;International Journal of Antimicrobial Agents;2024-05

5. Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP;Antibiotics;2024-03-25